ID
13154
Description
A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00559091
Link
https://clinicaltrials.gov/show/NCT00559091
Keywords
Versions (1)
- 1/20/16 1/20/16 -
Copyright Holder
CC BY-NC 3.0
Uploaded on
January 20, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Acute Myelocytic Leukemia NCT00559091
Eligibility Acute Myelocytic Leukemia NCT00559091
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
uncontrolled central nervous system involvement by aml
Data type
boolean
Alias
- UMLS CUI [1]
- C3714787
Description
NYHA
Data type
boolean
Alias
- UMLS CUI [1]
- C1275491
Description
intercurrent illness or medical condition precluding safe administration of ribavirin
Data type
boolean
Alias
- UMLS CUI [1]
- C0035525
Description
received any previous therapy within 28 days prior to study entry.hydrea is permitted but must be stopped 7 days prior to starting study drug
Data type
boolean
Alias
- UMLS CUI [1]
- C0020402
Description
HIV
Data type
boolean
Alias
- UMLS CUI [1]
- C0019682
Similar models
Eligibility Acute Myelocytic Leukemia NCT00559091
- StudyEvent: Eligibility
C0232741 (UMLS CUI [2])